Can you take Bcg vaccine with Nelarabine?

BCG vaccine has a major potential interaction with Fever.

The use of BCG vaccine is contraindicated in patients with fever unless the cause has been determined and evaluated. If the fever is due to an infection, administration of BCG vaccine should be deferred until the patient is afebrile and done with antimicrobial therapy. When BCG vaccine is used for immunization against tuberculosis, the presence of existing infection, especially if moderate or severe, may increase the risk of an adverse host reaction and/or vaccine failure. BCG vaccine is not for the treatment of active tuberculosis. When administered intravesically for the treatment of bladder cancer, concomitant antimicrobial therapy can interfere with the effectiveness of the vaccine. Antimicrobial therapy should be evaluated to assess the effects on BCG activity. Finally, since BCG vaccine contains live bacteria, it can potentially cause a systemic BCG infection, particularly in acutely ill patients. Disseminated BCG infection has been fatal in some cases.

Nelarabine has a major potential interaction with History, Radiation Therapy.

Severe neurologic adverse reactions have been reported with the use of nelarabine. Neurotoxicity is the dose-limiting toxicity of nelarabine. Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events. Close monitoring for neurologic adverse reactions is strongly recommended, when using nelarabine and therapy should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria Grade 2 or greater.

Nelarabine has a moderate potential interaction with Hyperuricemia Secondary to Chemotherapy.

Patients receiving nelarabine should receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumor lysis syndrome. Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.

BCG vaccine has a major potential interaction with Immunodeficiency.

The use of BCG vaccine is contraindicated in patients with congenital or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation). BCG vaccine contains live bacteria. The absence of immune competence may potentiate the replication of vaccine virus and cause a systemic BCG infection, which has been fatal in some cases. In addition, when used for immunization against tuberculosis, serum antibody response may be compromised. BCG vaccine should also not be administered to anyone with a family history of congenital or hereditary immunodeficiency until the individual's immune status can be assessed and is determined to be adequate.

BCG vaccine has a major potential interaction with Infection.

The use of BCG vaccine is contraindicated in patients with fever unless the cause has been determined and evaluated. If the fever is due to an infection, administration of BCG vaccine should be deferred until the patient is afebrile and done with antimicrobial therapy. When BCG vaccine is used for immunization against tuberculosis, the presence of existing infection, especially if moderate or severe, may increase the risk of an adverse host reaction and/or vaccine failure. BCG vaccine is not for the treatment of active tuberculosis. When administered intravesically for the treatment of bladder cancer, concomitant antimicrobial therapy can interfere with the effectiveness of the vaccine. Antimicrobial therapy should be evaluated to assess the effects on BCG activity. Finally, since BCG vaccine contains live bacteria, it can potentially cause a systemic BCG infection, particularly in acutely ill patients. Disseminated BCG infection has been fatal in some cases.

Nelarabine has a moderate potential interaction with Liver Disease.

The influence of hepatic impairment on the pharmacokinetics of nelarabine has not been evaluated. Because the risk of adverse reactions to this drug may be greater in patients with severe hepatic impairment (total bilirubin greater than 3 times upper limit of normal), it is recommended to closely monitor patients with severe liver dysfunction when treated with nelarabine.

Nelarabine has a major potential interaction with Neurological Disorders.

Severe neurologic adverse reactions have been reported with the use of nelarabine. Neurotoxicity is the dose-limiting toxicity of nelarabine. Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events. Close monitoring for neurologic adverse reactions is strongly recommended, when using nelarabine and therapy should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria Grade 2 or greater.

Nelarabine has a moderate potential interaction with Renal Dysfunction.

Nelarabine has not been studied in patients with renal dysfunction. There are insufficient data to support a dose recommendation for patients with a CrCl less than 50 mL/min. Because the risk of adverse reactions to this drug may be greater in patients with moderate (CrCl 30 to 50 mL/min) or severe (CrCl less than 30 mL/min) renal impairment, these patients should be closely monitored for toxicities if treated with this drug.

BCG vaccine has a major potential interaction with Tuberculosis, Active.

The use of BCG vaccine is contraindicated in patients with fever unless the cause has been determined and evaluated. If the fever is due to an infection, administration of BCG vaccine should be deferred until the patient is afebrile and done with antimicrobial therapy. When BCG vaccine is used for immunization against tuberculosis, the presence of existing infection, especially if moderate or severe, may increase the risk of an adverse host reaction and/or vaccine failure. BCG vaccine is not for the treatment of active tuberculosis. When administered intravesically for the treatment of bladder cancer, concomitant antimicrobial therapy can interfere with the effectiveness of the vaccine. Antimicrobial therapy should be evaluated to assess the effects on BCG activity. Finally, since BCG vaccine contains live bacteria, it can potentially cause a systemic BCG infection, particularly in acutely ill patients. Disseminated BCG infection has been fatal in some cases.

Nelarabine has a moderate potential interaction with Tumor Lysis Syndrome.

Patients receiving nelarabine should receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumor lysis syndrome. Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.

Nelarabine has a major potential interaction with Vaccination.

Immunocompromised patients receiving nelarabine should avoid receiving live vaccines.